Search by PDG name  
   

 

ABL1  
    


    
      Official symbol:  ABL1
      Full name:  ABL proto-oncogene 1, non-receptor tyrosine kinase
      Location:  9q34.12
      Also known as:  ABL, c-ABL, JTK7, p150
      Entrez ID:  25
      Ensembl ID:  ENSG00000097007
      Summary:  This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [provided by RefSeq, Aug 2014]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.00  
Gscore (Del):  0.36  
 
Recurrently deleted in 2 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.12  (Driver)
 
Recurrently mutated in 2 cancer type(s)
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  17  (Driver)
 
Fusions detected in 10 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   CRISPR: STRONGLY SELECTIVE 
 RNAi: STRONGLY SELECTIVE 
   
   

    
      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  3418.51  (Percentile rank: 98.81%)
      PubTator score:  4611.85  (Percentile rank: 99.39%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.